<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961868</url>
  </required_header>
  <id_info>
    <org_study_id>P071241</org_study_id>
    <secondary_id>P071241</secondary_id>
    <secondary_id>2009-A00288-49</secondary_id>
    <secondary_id>PHRC-08-192</secondary_id>
    <nct_id>NCT02961868</nct_id>
  </id_info>
  <brief_title>Cohort Follow-up of Patients With Renal or Craniocervical Fibromuscular Dysplasia</brief_title>
  <acronym>PROFILE</acronym>
  <official_title>PROgression of FIbromuscular LEsions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation de Recherche sur l'Hypertension Artérielle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PROFILE is a cohort study evaluating the progression of fibromuscular dysplasia lesions. This
      study is the prospective dimension of ARCADIA registry (ClinicalTrials.gov Identifier:
      NCT02884141), which aims to document phenotypic and genetic traits in patients with renal
      and/or cervical artery fibromuscular dysplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      Fibromuscular dysplasia (FMD) is a group of nonatherosclerotic, noninflammatory arterial
      diseases that usually involve renal and carotid arteries. Patients with FMD may present with
      renovascular hypertension and/or with cerebrovascular symptoms. The prevalence of FMD in
      hypertensive patients is estimated at 4/1000. Angiographic classification includes the
      multifocal type, with multiple stenoses and the 'string-of-beads' appearance that is related
      to medial FMD, and tubular and focal types which are not clearly related to specific
      histological lesions. FMD may affect one or more vascular beds and progress to more severe
      stenosis and to renal or cerebrovascular complications. FMD appears to be familial in 10% of
      cases (OMIM #135580).

      Renal artery FMD may progress to more severe stenosis and to renal atrophy, and/or to
      stenoses affecting more arteries within or outside the renal vasculature. The risk of
      progression as assessed from available studies was probably overestimated because
      documentation of progression was obtained from angiography, a procedure which is not
      routinely undertaken in patients with favourable clinical and biological outcomes. The
      disease is progressive, however, and literature stated that patients with FMD should undergo
      yearly duplex ultrasonography to detect progression of disease, restenosis, or loss of kidney
      volume.

      There are very few data on prognosis of patients with symptomatic carotid or vertebral artery
      FMD. The risk of arterial disease progression over time is unknown. The risk of ischemic
      stroke ranged from 0 to about 3% per year in the few studies which assessed that issue.

      Objectives

      The primary objective is to estimate the incidence and risk factors for progression of FMD
      lesions. This will be assessed by comparison between initial and 3 years abdominal and
      supra-aortic trunks vascular imaging (angiography, CT-angiography or Magnetic Resonance (MR)
      angiography), monitoring of downstream consequences development of lesions progression and
      clinical events.

      The secondary objectives are:

        -  to estimate rate of genetic polymorphism that may influence disease progression or be
           associated with complications

        -  to assess the frequency of multi-site FMD (common objective with the ARCADIA study)

        -  to collect standardized clinical, radiological, and biological data in patients with FMD
           through a national registry (common objective with the ARCADIA study)

        -  to organize a clinical, radiological and biological database and a biobank that will
           constitute a unique resource to initiate further clinical research (common objective
           with the ARCADIA study).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2009</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of fibromuscular dysplasia lesions confirmed by imaging</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>Inclusion, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney height</measure>
    <time_frame>Inclusion, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical event: revascularization procedure in a lesion site</measure>
    <time_frame>Through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical event: renal infarction</measure>
    <time_frame>Through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical event: ischemic stroke</measure>
    <time_frame>Through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical event: arterial dissection in a lesion site or downstream from a lesion site</measure>
    <time_frame>Through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical event: aneurysm rupture in a lesion site or downstream from a lesion site</measure>
    <time_frame>Through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of multisite fibromuscular dysplasia confirmed by imaging</measure>
    <time_frame>Inclusion, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single nucleotide polymorphisms</measure>
    <time_frame>Inclusion</time_frame>
    <description>Assessed by genome-wide association</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasminogen/plasmin level</measure>
    <time_frame>Inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matrix metalloproteinases level</measure>
    <time_frame>Inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>Fibromuscular Dysplasia</condition>
  <arm_group>
    <arm_group_label>Prospective cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 years follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Abdominal and supra-aortic trunks vascular imaging</intervention_name>
    <description>Abdominal and supra-aortic trunks vascular imaging (angiography, CT-angiography or MR-angiography) will be performed 3 years after inclusion. This imaging will be compare to initial imaging (which is a part of usual care, not an intervention added by the study) in order to assess FMD progression.</description>
    <arm_group_label>Prospective cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood sampling (genetic)</intervention_name>
    <description>A sample of blood will be taken to meet the objective of estimating the rate of genetic polymorphism that may influence disease progression or be associated with complications.</description>
    <arm_group_label>Prospective cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling (biomarkers)</intervention_name>
    <description>A sample of blood will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.</description>
    <arm_group_label>Prospective cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urine sampling</intervention_name>
    <description>A sample of urine will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.</description>
    <arm_group_label>Prospective cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with renal or craniocervical fibromuscular dysplasia diagnosed during the 2
             years before inclusion

          -  The fibromuscular dysplasia is documented by imaging (angiography, CT-angiography,
             MR-angiography) of less than 2 years and validated by a radiologist investigator

          -  Patient who understood and signed inform consent form

          -  Affiliated to the French health insurance system

          -  Available for a 3 years follow-up

        Exclusion Criteria:

          -  Patient with renal or craniocervical atherosclerosis, or inflammatory vascular disease
             as dominant pathological features

          -  Patient with renal or craniocervical arteries dissection or aneurysm without any other
             evidence of fibromuscular dysplasia

          -  Patient under 18 or under tutorship

          -  Known pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-François Plouin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <state>Brussels-Capital Region</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy institut Louis-Mathieu</name>
      <address>
        <city>Vandeuvre-les-Nancy</city>
        <state>Alsace-Champagne-Ardenne-Lorraine</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux hopital Saint-Andre</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine-Limousin-Poitou-Charentes</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand hopital Gabriel-Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne-Rhone-Alpes</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble hopital Albert-Michallon</name>
      <address>
        <city>La Tronche</city>
        <state>Auvergne-Rhone-Alpes</state>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille hopital cardiologique</name>
      <address>
        <city>Lille</city>
        <state>Hauts-de-France</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille hopital Roger-Salengro</name>
      <address>
        <city>Lille</city>
        <state>Hauts-de-France</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles hopital Andre Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <state>Ile-de-France</state>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP hopital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Sainte-Anne</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP hopital Bichat-Claude-Bernard</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP hopital Tenon</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse hopital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <state>Languedoc-Roussillon-Midi-Pyrenees</state>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen hopital Cote de Nacre</name>
      <address>
        <city>Caen</city>
        <state>Normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <state>Provence-Alpes-Cote d'Azur</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Artery Obstruction</keyword>
  <keyword>Carotid Artery Diseases</keyword>
  <keyword>Genetic Association Studies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromuscular Dysplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

